SMC Spain

A study published today analyses 185 cases of monkeypox reported in Spain up to 11 July.

Science magazine has published a report revealing multiple indications of fraud in one of the most cited publications on Alzheimer's disease. We explain what it means for the science that studies this disease.

The Council of Ministers on Monday approved a package of urgent energy efficiency and energy saving measures, including limiting the thermostat on air conditioning and heating in transport, workplaces and shops.

A study published in PNAS sets out a worst-case scenario for current climate change, explains the likelihood of its occurrence and analyses the devastating consequences it would have. It also includes a research agenda to address it.

Compared to Neanderthals and apes, modern humans experience fewer chromosomal inheritance errors when their brains develop, according to a new study published in Science Advances.

Glioblastoma is an aggressive type of cancer that arises in the brain or spinal cord. Researchers have identified a new drug that exploits DNA repair defects to selectively target tumours that are resistant to chemotherapy treatment with temozolomide. The research is published in Science.

Research conducted on more than 25,800 healthy adults aged 50 and older in the United States concludes that taking vitamin D supplements does not reduce the risk of bone fractures. The study is published in The New England Journal of Medicine.

A study published in the journal Nature has found that ancient human populations consumed milk during adulthood long before we were able to digest lactose beyond infancy. The genetic variant that allows us to do so was not increased in frequency by milk consumption, but by famine and infection, according to their hypothesis.

With the increase in monkeypox cases worldwide, the World Health Organisation has declared the outbreak an international public health emergency. There is now a recommended vaccine for its prevention or mitigation. Here is what we know about it and what the current recommendations are.

The European Medicines Agency (EMA) is still considering the approval of Hipra's SARS-CoV-2 vaccine. In mid-May, Hipra said it was ready to "have the vaccine available in a few days" following EMA approval, which it expected by the middle of this year, but which is being delayed until at least after July, as Elia Torroella, Hipra's R&D and Registration Director, explained at a breakfast briefing organised by the company today.